Cytotoxic T lymphocyte-associated antigen 4 rs231775 polymorphism and osteosarcoma

Abstract

Systematic reviews on osteosarcoma have concluded that CTLA4 rs231775 AA genotype influences risk for the disease in the Chinese population. Remarkably, rs231775 shows different frequencies in different human populations. Therefore, it would be interesting to know whether this SNP is related to the risk of osteosarcoma in other populations. The present study aimed to evaluate the association between rs231775 and the susceptibility of osteosarcoma in the Spanish population. We performed an updated meta-analysis including a total of 538 cases and 623 controls. The genotypic association analyses showed that the CTLA4 rs231755 was associated with osteosarcoma susceptibility in the Spanish population. When meta-analysis was performed, the results displayed that CTLA4 rs231775 AA genotype was associated with the risk of developing osteosarcoma in all analyzed populations (OR=2.07; 95% CI: 1.48-2.89).The rs231775 AA genotype could be considered as a susceptibility marker in osteosarcoma Keywords: CTLA4, rs231775, +49A/G and osteogenic sarcoma.

Association of The Cytotoxic T Lymphocyte Antigen-4 +49G/A Gene Polymorphism with Susceptibility to Malignant Bone Tumors

“…In the year 2012, Yang et al demonstrated the fact that the CTLA-4 + 49AA genotype had a 2.03-fold increased to the susceptibility to Ewing's sarcoma 19 . Bilbao-Aldaiturriaga et al discovered that the AG + GG genotype might be a safeguarding impact to osteosarcoma susceptibility 6 . Here upon, we therefore carried out the current meta-analysis for the purpose of investigating the more precise correlation existing between the + 49G/A of the CTLA-4 gene and the susceptibility to the malignant bone tumors.…”

“…Subsequent to removing the duplicated articles, after the scanning of the titles as well as the abstracts of these research works, with an aggregate of 50 research works remained. Thereafter, we carried out the evaluation of the full-text, together with excluding the ineligible studies; also, 6 case-control research works, having an aggregate of 2609 participants, were counted on in the present meta-analysis 6,[18][19][20][21][22] . The key features of the included research works are demonstrated in Table 1.…”

“…Despite considerable development in treating the tumors during the previous decade, the patients having malignant bone tumors prognosis continue to be unsatisfactory, the 5-year relative survival rate is almost 60% 1,3 . Nevertheless, it is quite likely that there are gene-environment interactions in the carcinogenesis of the malignant bone tumors; also, the genetic susceptibility is also likely to make contribution to the variable individual to the malignant bone tumors susceptibility [6][7][8] .…”

Associations between inflammatory gene polymorphisms (TNF-α 308G/A, TNF-α 238G/A, TNF-β 252A/G, TGF-β1 29T/C, IL-6 174G/C and IL-10 1082A/G) and susceptibility to osteosarcoma: a meta-analysis and literature review

“…Multiple factors are involved in the etiology of OS, among which genetics and gene polymorphisms have aroused increased attention [ 1 , 4 , 8 ]. Given the important roles of inflammation and gene polymorphisms in cancer etiology and progression, more studies have been performed to explore the associations between inflammatory gene polymorphisms and susceptibility to OS [ 26 , 29 , 32 , 33 , 36 – 40 , 48 , 49 ]. Although several studies including Patio-Garcia et al [ 36 ], Oliveira et al [ 26 ], Zhao et al [ 29 ] and Xie et al [ 37 ] have explored the possible association between TNF-α 308G/A polymorphism and OS risk, there results are inconsistent.…”

Genetic susceptibility to bone and soft tissue sarcomas: a field synopsis and meta-analysis

“…Looking at the already existing international literature, some investigators have meta-analyzed the evidence regarding a handful of SNPs such as XRCC3 rs861539 [ 4 ], MDM2 rs2279744 [ 5 , 6 ], and CTLA4 rs231775 [ 7 ]: however, to the best of our knowledge no comprehensive collection of the available data in this field of oncology has been published thus far.…”